MERRELL DOW NICORETTE ANTI-SMOKING Rx CHEWING GUM TRADE SHIPMENTS
Executive Summary
MERRELL DOW NICORETTE ANTI-SMOKING Rx CHEWING GUM TRADE SHIPMENTS will begin in the last half of February. The company anticipates that the product will be widely available at the retail level by March 1. The average whsle. price for a box of 96, 2 mg pieces of the gum will be $14.21. The product is expected to be priced at the retail level at about $20 per box. Nicorette received FDA approval on Jan. 13. Merrell Dow plans to hold a press conference on the product in NYC on Jan. 24. According to FDA-approved labeling, Nicorette is indicated as a "temporary aid to the cigarette smoker seeking to give up his or her smoking habit while participating in a behavioral modification program under medical surpervision." The labeling states that "the efficacy of Nicorette as an aid to smoking cessation was demonstrated in clinical studies which showed that Nicorette gum, in comparison to control chewing gums, increased the likelihood of smoking cessation among participants in behavior modification programs. As used in the context of this labeling, behavioral modification refers to supervised programs of education, counseling and psychological support. The efficacy of Nicorette use without concomitant participation in a behavioral modification program has not been established." According to the package insert, smokers most likely to benefit from Nicorette use are those "who have a high physical type dependence on nicotine." FDA approved Nicorette after a 34-month review; the NDA was filed in March 1981. The U.S. data submitted by the firm included studies involving over 100 MDs and 3,000 patients. The product was recommended for approval last June by FDA's Drug Abuse Advisory Cmte. That group also urged in October that Nicorette be marketed without DEA scheduling controls. Merrell Dow licensed Nicorette from AB Leo (Sweden). The Swedish firm is manufacturing the product for Merrell Dow.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth